Compare ALEMBIC PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FRESENIUS KABI ONCO. ALEMBIC PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 15.4 22.1 69.7% View Chart
P/BV x 3.5 3.1 114.0% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 ALEMBIC PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
ALEMBIC PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs664176 377.3%   
Low Rs41279 525.4%   
Sales per share (Unadj.) Rs208.737.7 553.8%  
Earnings per share (Unadj.) Rs31.05.1 608.6%  
Cash flow per share (Unadj.) Rs37.16.7 552.0%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.242.5 339.0%  
Shares outstanding (eoy) m188.52158.23 119.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.4 76.4%   
Avg P/E ratio x17.425.0 69.5%  
P/CF ratio (eoy) x14.518.9 76.6%  
Price / Book Value ratio x3.73.0 124.8%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46120,135 503.9%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m7,467703 1,061.8%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m39,3475,963 659.8%  
Other income Rs m9418 521.1%   
Total revenues Rs m39,4415,981 659.4%   
Gross profit Rs m8,7361,430 610.9%  
Depreciation Rs m1,152258 446.8%   
Interest Rs m184-26 -708.1%   
Profit before tax Rs m7,4931,216 616.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,568342 458.1%   
Profit after tax Rs m5,844806 725.1%  
Gross profit margin %22.224.0 92.6%  
Effective tax rate %20.928.1 74.3%   
Net profit margin %14.913.5 109.9%  
BALANCE SHEET DATA
Current assets Rs m19,5775,102 383.7%   
Current liabilities Rs m14,8962,385 624.5%   
Net working cap to sales %11.945.6 26.1%  
Current ratio x1.32.1 61.5%  
Inventory Days Days90150 59.8%  
Debtors Days Days45113 40.0%  
Net fixed assets Rs m27,0975,148 526.3%   
Share capital Rs m377158 238.3%   
"Free" reserves Rs m26,8116,556 409.0%   
Net worth Rs m27,1886,732 403.9%   
Long term debt Rs m4,993952 524.4%   
Total assets Rs m47,77810,388 459.9%  
Interest coverage x41.7-45.8 -91.1%   
Debt to equity ratio x0.20.1 129.8%  
Sales to assets ratio x0.80.6 143.5%   
Return on assets %12.67.5 168.0%  
Return on equity %21.512.0 179.5%  
Return on capital %23.614.6 161.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m19,4535,298 367.2%   
Fx outflow Rs m6,0651,772 342.2%   
Net fx Rs m13,3883,525 379.8%   
CASH FLOW
From Operations Rs m8,1201,274 637.3%  
From Investments Rs m-7,556-1,204 627.5%  
From Financial Activity Rs m590-196 -301.1%  
Net Cashflow Rs m1,153-126 -913.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 2.9 0.3 966.7%  
FIIs % 9.1 9.6 94.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 9.1 152.7%  
Shareholders   49,328 42,599 115.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FDC LTD.  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

ALEMBIC PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Sep 19, 2019 | Updated on Sep 19, 2019

ALEMBIC PHARMA share price has surged by 5% and its current market price is Rs 525. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index is ALEMBIC PHARMA (up 5.4%). The top losers are STRIDES PHARMA SCIENCE (down 0.1%) and THYROCARE TECHNOLOGIES (down 0.1%).

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS